JP2024504124A - 新規の抗グレムリン１抗体 - Google Patents

新規の抗グレムリン１抗体 Download PDF

Info

Publication number
JP2024504124A
JP2024504124A JP2023543120A JP2023543120A JP2024504124A JP 2024504124 A JP2024504124 A JP 2024504124A JP 2023543120 A JP2023543120 A JP 2023543120A JP 2023543120 A JP2023543120 A JP 2023543120A JP 2024504124 A JP2024504124 A JP 2024504124A
Authority
JP
Japan
Prior art keywords
seq
sequence
cancer
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023543120A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024504124A5 (https=
JPWO2022152290A5 (https=
Inventor
キアン，シュエミン
ツイ，スーリー
リー，ホンジュン
スン，ディー
グオ，フアンフアン
Original Assignee
スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド filed Critical スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド
Publication of JP2024504124A publication Critical patent/JP2024504124A/ja
Publication of JP2024504124A5 publication Critical patent/JP2024504124A5/ja
Publication of JPWO2022152290A5 publication Critical patent/JPWO2022152290A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023543120A 2021-01-18 2022-01-17 新規の抗グレムリン１抗体 Pending JP2024504124A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/072397 2021-01-18
CN2021072397 2021-01-18
CN2021142043 2021-12-28
CNPCT/CN2021/142043 2021-12-28
PCT/CN2022/072297 WO2022152290A1 (en) 2021-01-18 2022-01-17 Novel anti-gremlin1 antibodies

Publications (3)

Publication Number Publication Date
JP2024504124A true JP2024504124A (ja) 2024-01-30
JP2024504124A5 JP2024504124A5 (https=) 2025-01-24
JPWO2022152290A5 JPWO2022152290A5 (https=) 2025-01-24

Family

ID=82446960

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023543120A Pending JP2024504124A (ja) 2021-01-18 2022-01-17 新規の抗グレムリン１抗体

Country Status (10)

Country Link
US (1) US20240294622A1 (https=)
EP (1) EP4277927A4 (https=)
JP (1) JP2024504124A (https=)
KR (1) KR20230132544A (https=)
CN (1) CN116848135A (https=)
AU (1) AU2022207030A1 (https=)
CA (1) CA3208455A1 (https=)
MX (1) MX2023008423A (https=)
TW (1) TW202241944A (https=)
WO (1) WO2022152290A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023018204A2 (pt) * 2021-03-11 2023-10-24 Univ Shanghai Jiaotong Método de tratamento de doenças usando antagonistas de gremlin1
GB202205200D0 (en) * 2022-04-08 2022-05-25 Ucb Biopharma Sprl Combination with chemotherapy
GB202205203D0 (en) * 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
WO2024213066A1 (en) * 2023-04-13 2024-10-17 Suzhou Transcenta Therapeutics Co., Ltd. Combination therapies involving grem1 antagonists for treatment of cancer
WO2025148900A1 (en) * 2024-01-08 2025-07-17 Suzhou Transcenta Therapeutics Co., Ltd. Combination therapy of grem1 antagonist and activin receptor antagonist for treating pah
CN117801109B (zh) * 2024-03-01 2024-05-03 再少年(北京)生物科技有限公司 iPS诱导定向分化成内皮祖细胞的方法及应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015512894A (ja) * 2012-03-15 2015-04-30 エスエヌユー アールアンドディービー ファウンデーション グレムリン−１に対する抗体
JP2016519650A (ja) * 2013-03-14 2016-07-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒト抗ｇｒｅｍ１抗体
JP2019529371A (ja) * 2016-08-29 2019-10-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 肺動脈性肺高血圧を処置するための抗グレムリン−１（ｇｒｅｍ１）抗体およびその使用の方法
WO2019243801A1 (en) * 2018-06-18 2019-12-26 UCB Biopharma SRL Gremlin-1 antagonist for the prevention and treatment of cancer
JP2020511946A (ja) * 2016-12-19 2020-04-23 ユーシービー バイオファルマ エスアールエル グレムリン−１の結晶構造及び阻害抗体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023018204A2 (pt) * 2021-03-11 2023-10-24 Univ Shanghai Jiaotong Método de tratamento de doenças usando antagonistas de gremlin1

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015512894A (ja) * 2012-03-15 2015-04-30 エスエヌユー アールアンドディービー ファウンデーション グレムリン−１に対する抗体
JP2016519650A (ja) * 2013-03-14 2016-07-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒト抗ｇｒｅｍ１抗体
JP2019529371A (ja) * 2016-08-29 2019-10-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 肺動脈性肺高血圧を処置するための抗グレムリン−１（ｇｒｅｍ１）抗体およびその使用の方法
JP2020511946A (ja) * 2016-12-19 2020-04-23 ユーシービー バイオファルマ エスアールエル グレムリン−１の結晶構造及び阻害抗体
WO2019243801A1 (en) * 2018-06-18 2019-12-26 UCB Biopharma SRL Gremlin-1 antagonist for the prevention and treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PLOS ONE, vol. Vol. 7, Issue 4, e35100, JPN6025052645, 2012, pages 1 - 8, ISSN: 0005761626 *

Also Published As

Publication number Publication date
EP4277927A4 (en) 2025-07-23
CN116848135A (zh) 2023-10-03
TW202241944A (zh) 2022-11-01
AU2022207030A9 (en) 2024-09-19
US20240294622A1 (en) 2024-09-05
WO2022152290A1 (en) 2022-07-21
CA3208455A1 (en) 2022-07-21
AU2022207030A1 (en) 2023-08-24
EP4277927A1 (en) 2023-11-22
KR20230132544A (ko) 2023-09-15
MX2023008423A (es) 2023-07-26

Similar Documents

Publication Publication Date Title
JP7624484B2 (ja) 新規抗ｐｄ－ｌ１抗体
US20210388105A1 (en) Novel anti-cd39 antibodies
JP2022105085A (ja) 改変ｊ鎖を有する結合分子
US20240294622A1 (en) Novel anti-gremlin1 antibodies
JP2023538945A (ja) 抗ｒｏｒ１抗体及び関連の二重特異性結合タンパク質
US12240901B2 (en) Humanized anti-BASIGIN antibodies and the use thereof
US12540183B2 (en) Anti-CD4 antibodies
IL304096A (en) Pd-1 binding molecule and application thereof
KR20250152073A (ko) 항체, 항원 결합 단편 및 사용 방법
KR102486507B1 (ko) 플렉틴-1 결합 항체 및 그의 용도
US20240190986A1 (en) Mesothelin binding molecule and application thereof
WO2022194201A1 (zh) 一种靶向cldn18.2的抗体或其抗原结合片段及其应用
EP4410834A1 (en) Ctla-4 binding molecule and use thereof
TW202602921A (zh) 多功能ｎｋ細胞接合器
US20250215092A1 (en) Human Epidermal Growth Factor Receptor Binding Molecule and Use Thereof
WO2024165031A1 (zh) 三特异性抗原结合分子及其应用
HK40093421A (zh) 新颖的抗gremlin1抗体
RU2844869C1 (ru) Антитела против ror1 и родственные биспецифичные связывающие белки
WO2025140619A1 (zh) 包含ccr8抗原结合结构域的多特异性抗体
JP2026510317A (ja) 抗ｃｌｄｎ６及び抗ｃｄ３多重特異性抗体及び使用方法
HK40055449A (en) Novel anti-cd4 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260323